8-K: Hepion Pharmaceuticals Terminates Merger Agreement with Pharma Two B, Cancels Stockholder Meeting

Hepion Pharmaceuticals has terminated its merger agreement with Pharma Two B due to Nasdaq's burn rate calculation, leading to the cancellation of a special stockholder meeting.

Summary

• Hepion Pharmaceuticals terminated its merger agreement with Pharma Two B on December 10, 2024, due to Nasdaq's decision not to exclude historical losses from the burn rate calculation.
• The termination agreement was mutually agreed upon, and no termination fees will be paid by either party.
• As a result of the termination, Hepion has cancelled its special stockholder meeting scheduled for December 12, 2024.
• The proposals outlined in the Definitive Proxy Statement filed on November 8, 2024, have also been withdrawn from consideration by stockholders.
• A promissory note of $600,000 from Pharma Two B to Hepion, dated July 19, 2024, remains in effect and is now immediately due with all outstanding principal and interest payable to Hepion.

Sentiment

Score: 3

Explanation: The termination of the merger agreement and cancellation of the stockholder meeting are significant negative events, indicating a setback in the company's strategic plans. The need for additional financing and the uncertainty of clinical trial outcomes further contribute to a negative sentiment.

Positives

• The termination was a mutual decision, avoiding termination fees for both parties.
• The $600,000 promissory note from Pharma Two B is now due to Hepion, providing immediate cash flow.

Negatives

• The merger agreement with Pharma Two B has been terminated.
• The special stockholder meeting has been cancelled.
• The proposals outlined in the Definitive Proxy Statement have been withdrawn.

Risks

• Hepion's ability to continue as a going concern is uncertain.
• The company needs additional financing.
• There are risks associated with patent protection and litigation.
• Clinical trials are lengthy and expensive, with uncertain outcomes.
• There are risks related to obtaining FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

Hepion is continuing efforts, to the extent that cash is available, to provide any value derived from rencofilstat to its shareholders and is exploring strategic and financing alternatives.

Management Comments

• Hepion announced that it has entered into a termination agreement with Pharma Two B Ltd.
• Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled.

Industry Context

The termination of the merger agreement highlights the challenges faced by biopharmaceutical companies in securing funding and navigating regulatory hurdles, particularly in the competitive NASH drug development landscape.

Comparison to Industry Standards

• The termination of the merger agreement is a setback for Hepion, as mergers are often seen as a way to consolidate resources and accelerate drug development.
• Other companies in the NASH space, such as Intercept Pharmaceuticals and Madrigal Pharmaceuticals, have faced similar challenges in clinical trials and regulatory approvals.
• The need for additional financing and the uncertainty of clinical trial outcomes are common risks in the biopharmaceutical industry.

Stakeholder Impact

• Shareholders will be impacted by the termination of the merger agreement and the cancellation of the stockholder meeting.
• Employees may face uncertainty due to the strategic restructuring and exploration of alternatives.
• The company's future direction is uncertain, which may affect suppliers and other stakeholders.

Next Steps

• Hepion will continue efforts to provide value from rencofilstat to shareholders.
• Hepion will explore strategic and financing alternatives.

Key Dates

Keywords

Merger Agreement, Termination, Hepion Pharmaceuticals, Pharma Two B, Nasdaq, Stockholder Meeting, Promissory Note, Burn Rate, Rencofilstat, NASH